Effect of Local Treatment(Carrageenan Nasal Spray and PVP-I Mouthwash) in Reducing Viral Load in Patients With COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-24

Study Completion Date

2022-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to recruit confirmed Covid-19 patients, to evaluate whether the topical anti-septic can improve clinical outcome in early Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection. During the global pandemic period, an effective and highly available method once be identified, it will reduce the risk of disease transmission and lower the medical burden.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome

NCT03141554

Oral Health

COMPLETED PHASE4

Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19

NCT04603794

COVID-19

UNKNOWN PHASE4

Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19

NCT04344236

COVID-19

WITHDRAWN PHASE2

[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse

NCT04719208

Covid19

UNKNOWN NA

A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients

NCT04341688

Covid-19

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Oral and nasal disinfection, a simple method with the application of commonly used antiseptic agents is frequently performed in the otolaryngology and dental practice. The ability to deactivate viral particles with a good safety profile may be an important benefit in the control of viral proliferation and shedding. Actually, multiple anti-septic agents demonstrated virucidal properties against SARS-CoV-2 in several in vitro studies. Among these, Povidone-Iodine (PVP-I), common usage in otolaryngology operation and topical therapy, showed high virucidal properties (0.45% PVP-I, throat spray, 4-log drop in viral load) and of great safety. There is also evidence that topical usage of saline can decrease the severity of upper respiratory tract infection. In addition, carrageenan, a sulphated polysaccharide purified from red marine algae, had shown efficacy in inhibiting multiple viruses, including in vitro studies of SARS-CoV-2. Some randomized controlled trials had also shown their abilities in improving patients' symptoms with a good safety profile. Multiple international organizations are conducting relating randomized clinical trials to evaluate whether the topical anti-septic improves clinical outcomes after early SARS-CoV-2 infection. The added value of topical antiseptic agents may be beneficial in improving symptoms, reducing viral load and alleviating the rate of disease progression. Due to relatively low risk, well-toleration to the general population, and highly available characteristics, the potential benefits of these agents deserve more attention.

The goal of this study is to investigate the changes in clinical symptoms and sequential laboratory data in confirmed COVID-19 adult patients at the early disease stage. By applying topical anti-septic which is frequently used in otolaryngology procedures, the investigators will evaluate the impact of this intervention on the symptoms, viral load and the rate of disease progression. During the global pandemic period, an effective and highly available method once be identified, it will reduce the risk of disease transmission and lower the medical burden.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 SARS-CoV 2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Topical medical treatment

Intranasal spray and oral gargling

Group Type EXPERIMENTAL

Carrageenan nasal spray and 1% PVP- mouthwash and gargle

Intervention Type DRUG

Day1 to Day7

1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time
2. Oral gargling 3 times/day, 15cc/per time

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carrageenan nasal spray and 1% PVP- mouthwash and gargle

Day1 to Day7

1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time
2. Oral gargling 3 times/day, 15cc/per time

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BETADINE™ Cold Defense Nasal Spray and Povidone Iodine Mouthwash and Gargle

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. age older than 20 years of age
2. admission with a confirmed positive test for SARS-CoV-2 infection by reverse transcription polymerase chain reaction (RT- PCR)
3. disease onset (start of COVID-19 symptom and PCR test) for ≤ 120 hours
4. available informed consent of this study.
5. Full COVID-19 vaccination(at least after 2nd dose of TFDA-approved vaccine 14 days)

Exclusion Criteria

1. receiving oxygen supply before intervention
2. known intolerance/allergy to the study drugs
3. pregnancy
4. sinus/oral operation within 30 days of the beginning of the study
5. using intranasal medication before randomization
6. no available informed consent
7. inability to self-care or reply to questionnaire

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No